Wednesday, June 10, 2026
🇺🇸 FDA

P1 · Therapeutic area intelligence

Oncology patent intelligence

Anticancer agents, immuno-oncology, ADC, and oncology patent filings — grants, expirations, and assignee activity.

Patents
2,004

Quick answer

2,004 US pharmaceutical patents in our index match Oncology title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 10272113

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Apr 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10272099

    Tumor-selective combination therapy

    The Board of Regents of the University of Texas System · Granted Tue Apr 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10273281

    CD80 extracellular domain polypeptides and their use in cancer treatment

    Five Prime Therapeutics, Inc. · Granted Tue Apr 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10265282

    Cancer treatment

    VANDA PHARMACEUTICALS INC. · Granted Tue Apr 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10265394

    Compositions and methods for self-adjuvanting vaccines against microbes and tumors

    The Regents of the University of California · Granted Tue Apr 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10258600

    Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics

    Northwestern University · Granted Tue Apr 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10260101

    C-kit oncogene mutations in melanoma

    The Regents of the University of California · Granted Tue Apr 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10258635

    Formulations and compositions of vitamin D analogs for treating and preventing cancer and other diseases

    Aphios Corporation · Granted Tue Apr 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10251912

    MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Apr 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10238652

    Compounds for treatment of cancer

    Curegenix, Inc. · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10238734

    Compositions and methods for self-adjuvanting vaccines against microbes and tumors

    The Regents of the University of California · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10239954

    Antibodies specific for urokinase-type plasminogen activator and methods of use thereof for treating cancer

    The Regents of the University of California · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10231949

    Inhibition of cancer cell motility

    Northwestern University · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10233463

    Neurotensin-induced tumor formation is regulated by micro RNA 133A-aftiphilin-dependent receptor recycling

    The Regents of the University of California · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 2019076525

    THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER

    GANYMED PHARMACEUTICALS GMBH [DE] · Granted Thu Mar 14 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Mar 09 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. CA 3075215

    INHIBITEUR DE L'HISTONE DESACETYLASE EN ASSOCIATION AVEC UN MODULATEUR DE POINT DE CONTROLE IMMUNITAIRE POUR LA CANCEROTHERAPIE

    4SC AG [DE] · Granted Thu Mar 14 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Mar 09 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10227567

    Isolation and use of solid tumor stem cells

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Mar 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10226472

    Methods for the treatment of breast cancer

    Syndax Pharmaceuticals, Inc. · Granted Tue Mar 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10221244

    Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer

    Five Prime Therapeutics, Inc. · Granted Tue Mar 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10213414

    Glucocorticoid receptor modulators to treat pancreatic cancer

    Corcept Therapeutics Incorporated · Granted Tue Feb 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10213445

    Compositions and methods of diazeniumdiolate-based prodrugs for treating cancer

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Feb 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10214529

    Small molecules for the treatment of primary cancer and cancer metastasis

    The Board of Regents of the University of Texas System · Granted Tue Feb 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10206875

    Nanoemulsion compositions of taxoid drugs, and methods for the use thereof to target cancer cells and cancer stem cells

    Northwestern University · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10202397

    Anti-cancer compounds targeting Ral GTPases and methods of using the same

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Feb 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10202605

    Methods of identifying and treating poor-prognosis cancers

    THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Tue Feb 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10196443

    TEM8 antibodies and their use in treatment and detection of tumors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10195297

    Iron garnet nanoparticles for cancer radiotherapy and chemotherapy

    The Board of Regents of the University of Texas System · Granted Tue Feb 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10195259

    Compositions and methods for treatment of cancer using bacteria

    Decoy Biosystems, Inc. · Granted Tue Feb 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10188704

    Enhanced melanoma cancer prevention by novel melanotropins

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue Jan 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10188751

    Papillomavirus pseudoviruses for detection and therapy of tumors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jan 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10188654

    Uses of pyrimido-pyridazinones to treat cancer

    Asana BioSciences, LLC · Granted Tue Jan 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10182997

    Liposomal curcumin for treatment of cancer

    The Board of Regents of the University of Texas System · Granted Tue Jan 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10182984

    Targeted interferons demonstrate potent apoptotic and anti-tumor activities

    The Regents of the University of California · Granted Tue Jan 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10173074

    Cancer stem cell vaccination and treatment

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Jan 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10172937

    Method of treatment of malignant solid tumors with afucosylated anti-FGFR2IIIb antibodies

    Five Prime Therapeutics, Inc. · Granted Tue Jan 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10167334

    Treatment of cancer using anti-TGF-BETA and PD-1 antibodies

    The Regents of the University of California · Granted Tue Jan 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10167337

    Combination immunotherapy for the treatment of cancer

    The Board of Regents of the University of Texas System · Granted Tue Jan 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10166304

    Antibody fragments for detecting cancer and methods of use

    Regents of the University of Minnesota · Granted Tue Jan 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10166257

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Jan 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10155003

    Methods and compositions comprising ursolic acid and/or resveratrol for treating diabetes, or cancer

    The Board of Regents of the University of Texas System · Granted Tue Dec 18 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10155796

    Compositions and methods for inhibiting tumor cells by inhibiting the transcription factor ATF5

    The Regents of the University of California · Granted Tue Dec 18 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10154970

    Methods for immunomodulation of cancer and infectious disease therapy

    The Regents of the University of California · Granted Tue Dec 18 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10151756

    Predictive markers for polyamine inhibitor cancer therapies

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue Dec 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10150783

    Heterocyclic ITK inhibitors for treating inflammation and cancer

    Aclaris Therapeutics, Inc. · Granted Tue Dec 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10144753

    Anthracycline derivatives for treating tumor diseases

    Produkem Molekulares Design GMBH · Granted Tue Dec 04 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10144726

    Modulators of the p70S6 kinase for use in the treatment of brain disorders and triple-negative breast cancer

    SENTINEL ONCOLOGY LIMITED · Granted Tue Dec 04 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10138271

    Native and agonist CTL epitopes of the MUC1 tumor antigen

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Nov 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10137121

    Methods of treating cancer with farnesyltransferase inhibitors

    Kura Oncology, Inc. · Granted Tue Nov 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Oncology patents are indexed?

2,004 patents match our Oncology classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.